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ABSTRACT: Interleukin 17A (IL-17A) and complement (C9) activation have each been implicated in the pathogenesis
of idiopathic pulmonary fibrosis (IPF).Wehave reported that IL-17A induces epithelial injury viaTGF-b inmurine
bronchiolitis obliterans; that TGF-b and theC9 cascadepresent signaling interactions inmediating epithelial injury;
and that the blockade ofC9 receptorsmitigates lung fibrosis. In the present study,we investigated the role of IL-17A
in regulating C9 in lung fibrosis.Microarray analyses ofmRNA isolated from primary normal human small airway
epithelial cells indicated that IL-17A (100 ng/ml; 24 h; n= 5donor lungs) inducesC9 components (C9 factor B,C3, and
GPCR kinase isoform 5), cytokines (IL8, -6, and -1B), and cytokine ligands (CXCL1, -2, -3, -5, -6, and -16). IL-17A
induces protein andmRNA regulation of C9 components and the synthesis of active C9 3a (C3a) in normal primary
human alveolar type II epithelial cells (AECs). Wild-type mice subjected to IL-17A neutralization and IL-17A
knockout (il17a2/2) mice were protected against bleomycin (BLEO)-induced fibrosis and collagen deposition.
Further, BLEO-injured il17a2/2 mice had diminished levels of circulating Krebs Von Den Lungen 6 (alveolar
epithelial injurymarker), local caspase-3/7, and localendoplasmic reticularstress-relatedgenes.BLEO-induced local
C9 activation [C3a,C5a, and terminalC9 complex (C5b-9)]was attenuated in il17a2/2mice, and IL-17Aneutralization
prevented the loss of epithelial C9 inhibitors (C9 receptor-1 related isoformY and decay accelerating factor), and an
increase in local TUNEL levels. RNAi-mediated gene silencing of il17a in fibrotic mice arrested the progression of
lung fibrosis, attenuated cellular apoptosis (caspase-3/7) and lung deposition of collagen andC9 (C5b-9). Compared
tonormals, plasma from IPFpatients showed significantlyhigher hemolytic activity.Our findings demonstrate that
limiting complement activation by neutralizing IL-17A is a potential mechanism in ameliorating lung fibrosis.—
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Interleukin 17A (IL-17A) has important roles in in-
flammation (1, 2), epithelial injury (3), and fibrosis (4–6),
but the potential direct impact of IL-17A on complement
(C9) activation and the resulting lung injury and tissue
fibrosis in the pathogenesis of idiopathic pulmonary fi-
brosis (IPF) has not been established. It has also been re-
ported that at optimal physiologic doses, the combination
of IL-17A and C9 may even participate in the process of
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phagocytosis of microbes in the presence of vaccine-
induced antibodies (7). However, repeated exposure to
IL-17A has been shown to induce a positive feedback
regulation of C9 in multiple cell types, including tracheal
epithelium (2), human proximal tubular epithelium (8),
human colonic subepithelial myofibroblasts (9), and skin
fibroblasts (10). C9 activation—an essential arm of innate
immunity—is initially beneficial to the clearance of mi-
crobes and damaged cells, but the local release of ana-
phylatoxinsprimes thecells tosynthesizeprofibroticgenes
that eventually lead to fibrosis. Therefore, a better un-
derstanding of the interlinked immunologic mechanisms
of lung remodeling is essential to address a complex dis-
ease such as IPF.
Alveolar epithelial cells (AECs) have long been re-
ported as victims of the surrounding inflammatory mi-
croenvironment in IPF (11), and a recent single-cell RNA
sequencing report by Whitsett and colleagues (12) sug-
gested that individual epithelial cells purified from IPF
lungs frequently coexpresses selectivemarkers for AECs
(types I and II) and the conducting airways, demon-
strating indeterminate states of differentiation not seen
in normal lung development. Our prior reports showed
compelling evidence that indicate epithelial injury re-
lated to C9 activation in primary normal human
small airway epithelial cells (SAECs) (13) and IL-17A-
mediated epithelial-to-mesenchymal transition in im-
mortalized normal rat AECs (3). Therefore, in our
current study, we investigated the role of IL-17A in C9
activation in normal primary human AECs and SAECs.
Epithelial injury in IPF is strongly related to endoplasmic
reticulum (ER) stress (14–17) and the role of IL-17A in ER
stress has been reported in viral infection (18) and LPS
exposure (1). Further, AECs subjected to inflammatory
exposure and ER stress are reportedly susceptible to
AEC permeability, apoptosis, and cell death, as in-
dicated by levels of Krebs VonDen Lungen 6 (KL-6)/cell
surface–associated mucin isoform 1 (MUC-1) (19–23),
caspase-3/7 (24), and TUNEL (25). Our prior reports on
epithelial injury have implicated the signaling interac-
tions between IL-17A and TGF-b (3) and those between
C9 and TGF-b (13).We have reported C9 activation in the
murine bleomycin (BLEO)-induced lung fibrosis model,
wherein we detected elevated local levels of the ana-
phylatoxins [active C9 component 3a (C3a) and C5a] and
the soluble terminal C9 complex (C5b-9) (26). Other re-
ports of C9 have shown C4d deposition in chronic lung
transplant rejection (27) and prevention of sepsis- and
LPS-induced lung fibrosis by blockade of C5 protein (28)
(releases C5a via convertase) and C3 convertase (29),
respectively.Weused a clinically relevantmurinemodel to
mimic patients with IPF who present ongoing fibrosis (30,
31) and showed that the therapeutic blockade of receptors
for C3a or C5a mitigates lung fibrosis and systemic TGF-b
activity (26).Wills-Karpandcolleagues (2)haveshownthat
severe asthma is driven by dysregulated C3a/C5a control
of the IL-23–T helper 17 (Th17) axis, which leads to exces-
sive IL-17A production. This effect occurs as a result of a
shift from C5a-driven tolerance toward C3a-driven Th17
responses at the airway surface. To date, however, the
specific link between IL-17A–driven inflammation
and C9 activation which eventually lead to pulmonary
fibrosis has not been established.
The purpose of the current study was to investigate
the role of IL-17A in the regulation of C9 activation. To-
ward this end, we employed the low-dose chronic injury
model of lung fibrosis, and used 3 modes of interven-
tion, which included il17a2/2 mice, bioneutralization of
IL-17A with adenoviral vectors that express the soluble
murine receptor fusion protein, and a therapeutic in-
terventionwith small interference RNA (siRNA) specific
to il17a. Our studies of il17a2/2 mice revealed a critical
role for IL-17A in mediating C9 activation in addition to
cellular apoptosis, alveolar injury, and ER stress. Our
IL-17A neutralization studies confirmed that loss of
IL-17A bioactivity prevented the loss of epithelial C9
inhibitory proteins and cellular apoptosis. Finally, our
therapeutic studies arrested the progression of lung fi-
brosis, in addition to mitigating cellular apoptosis
and both C9 and collagen deposition. In addition, our in
vitro observations reveal that IL-17A robustly induces
C9-related gene and protein synthesis in both normal
primary human airway and AECs. Collectively, these
studies demonstrate that although lung remodeling is
triggered bymultiplemechanisms, limitingC9 activation
by neutralizing IL-17A is a potential mechanism in
ameliorating lung fibrosis.
MATERIALS AND METHODS
Cell culture
Normal primary human type II AECs (hAECs; Cell Biologics,
Chicago, IL, USA) were grown in human alveolar epithelial
basal medium supplemented with serum and growth factors
(Cell Biologics). The cells were seeded at 70% confluence and
incubated in 5% CO2–95% air. Before stimulation, the cells
were growth arrested in basal medium alone for 1 h. Normal
primary human SAECs (Cambrex Biosciences, Walkersville,
MD, USA) from 5 donor lungs were grown in small airway
basal medium supplemented with growth factors (Cambrex
Biosciences). Before stimulation, the cells were growth arres-
ted for 1 h in 0.01% serum or 1:100 growth factor–containing
medium.
Antibodies and other reagents
The antibodies used for immunoblot analysis or immunofluo-
rescent labeling are as follows: decay-accelerating factor (DAF)-
clone H-319 (sc-9156); and vinculin-clone7F9 (sc-73614) (Santa
CruzBiotechnology),C3a receptor (C3aR;NBP1-61567), andC5a
receptor (C5aR; NBP2-15649; Novus Biologicals, Littleton, CO,
USA). Recombinant proteins used in this study were human
IL-17A (14-8179; BD Biosciences, Franklin Lakes, NJ, USA). All
other reagents, unless otherwise specified, were fromMillipore-
Sigma (St. Louis, MO, USA).
Animal studies
The Animal Care and Use Committee at the University of
Michigan and Indiana University School of Medicine approved
the animalprotocols.BLEO(0.025U)was instilled intratracheally
in C57-BL6 mice (8 wk of age; The Jackson Laboratory, Bar
5544 Vol. 31 December 2017 CIPOLLA ET AL.The FASEB Journal x www.fasebj.org
Harbor, ME, USA), as previously described (26, 30, 31), with
minor modifications.
Human studies
Plasma samples from patients with IPF were obtained through
theNational InstitutesofHealth,NationalHeart,Lung, andBlood
Institute (Bethesda,MD,USA)LungTissueResearchConsortium.
Patient demographics of these samples have been reported (13)
and are presented in this report (Table 1). All protocols were
approved by the institutional review boards of the University of
Michigan and Indiana University School of Medicine.
Microarray analysis
SAECswere treatedwith IL-17A (100 ng/ml) for 24 h. RNAwas
isolated, and cDNA was subjected to microarray analysis
(Affymetrix; Thermo Fisher Scientific, Waltham, MA, USA) by
the Microarray Core (University of Texas Southwest Medical
Center, Dallas, TX, USA).
Real-time PCR
Real-time PCR was performed on cDNA from cell lysates, as
reported in several publications (3, 13, 26, 30, 31), by using gene-
specific Taqman assays (Thermo Fisher Scientific). The semi-
quantitative real-time PCR data for each target gene was
expressed as 22DDCt relative quantitation vs. endogenousb-actin,
with error bars representing the SE of triplicate reactions.
Western blot analysis of cell lysates
Cell lysates were subjected to immunoblot analysis, as has been
described (26).
ELISA
Conditioned medium collected from replicate human in vitro
studies was measured for active C3a by the MicroVue C3a Plus
EIA Kit (Quidel Corp., San Diego, CA, USA), according to the
manufacturer’s instructions. Acellular bronchoalveolar lavage
fluid (BALF) specimens derived from il17a2/2 mice or mice
treated with il17a-specific siRNA were used to measure the sol-
uble formofC5b-9with theTerminalC9ComplexC5b-9Bioassay
ELISA kit (U.S. Biologic Life Sciences, Salem, MA, USA), per the
manufacturer’s instructions. The active forms of C3a and C5a
were measured in the BALF samples by using the mouse C9
fragment 3a and 5a ELISA kits (My Biosource, San Diego, CA,
USA), respectively, per the manufacturer’s instructions. Murine
plasma was measured for KL-6/MUC1 with the Mouse Krebs
Von Den Lungen 6 ELISA Kit (BG-MUS11425; Novateinbio,
Woburn, MA, USA).
Immunofluorescence staining
AECs were fixed with 220°C methanol for 5 min. Cells were
washedand incubatedwithantibodies againstDAF(1:50) and the
corresponding concentration of IgG, followed by incubationwith
the secondary antibody FITC-labeled horseradish peroxidase
(HRP)-linked IgG (1:40; Jackson ImmunoResearch Laboratories,
West Grove, PA, USA), for 1 h each. Nuclei were counterstained
with (DAPI; Roche, Indianapolis, IN, USA). Staining was visual-
ized by an i90 fluorescencemicroscope and images capturedwith
NIS-Elements v.2.0 (both from Nikon, Melville, NY, USA).
Tissues were deparaffinized according to standard proto-
cols and permeabilized with proteinase K (10 mg/ml in 10 mM
Tris-HCl) for 30 min at 37°C. Nonspecific binding sites were
blocked with bovine serum albumin (1 mg/ml) in 50 mM
Tris-HCl for 10 min at 37°C. Incubation with the primary anti-
bodyZO-1 (1:50; Zymed, Carlsbad, CA, USA) anda-SMA (1:50;
Dako, Carpinteria, CA, USA) was followed by incubation with
the secondary antibodies rhodamine and FITC-labeled HRP-
linked IgG (1:40; Jackson ImmunoResearchLaboratories), for 1 h
each. Nuclei were counterstained with DAPI. Staining was vi-
sualized by an i90 fluorescence microscope and images were
captured with NIS-Elements v.2.0 (Nikon).
For the TUNEL assay, tissue sections were subjected to the
same protocol as described above until the nonspecific blocking
stage. TUNEL+ cells were detected with In Situ Cell Death De-
tectionKit, Fluorescein (Roche).Nucleiwere counterstainedwith
DAPI. To quantitate apoptosis, at least 3 mice per group were
examined, and a blinded observer counted the number of
TUNEL+ and DAPI+ cells in 3 independent fields per mouse. At
least 300 cells were analyzed per condition.
Caspase-3/7 assay
This assay detects caspase-3/7 activity based on the cleavage
of a profluorescent DEVD peptide-rhodamine 110 substrate
[(Z-DEVD)2-R110]. The reagent is prepared by combining
equal volumes of buffer and substrate (1:1). The contentswere
mixed and incubated for 2 h, and the fluorescent signal was
measured. The reagent permeabilizes the cells to release the
caspase, delivers the profluorescent substrate, and provides
optimized conditions to stabilize caspase activity. Upon cleav-
age of the substrates by the respective caspase, aminoluciferin is
liberated and contributes to the generation of light in a lumi-
nescence reaction. The resulting luminescent signal is directly
proportional to the amount of caspase activity present in the
sample. In the absence of active caspase, the caspase substrates
do not act as substrates for luciferase and thus produce no light.
Murine PCR microarrays
Total RNA was isolated from cells with an RNeasy Mini Kit
(Qiagen, Valencia, CA, USA) and was reverse transcribed by
using qScript cDNA SuperMix (Quanta BioSciences, Foster City,
TABLE 1. Baseline and pulmonary function characteristics of IPF
patients
Characteristic Data, means 6 SEM, n 5 23 Range
Age (yr) 64.2 6 1.7 48–80
Male (%) 65.2
Smoking status (%)
Current smoker 8.7
Former smoker 30.4
Never smoker 56.5
Smoking (pack yr)a 34.2 6 5.2 5–66
Pulmonary function test
FEV1% 86.0 6 4.8 48–138
FVC% 72.0 6 4.3 36–108
DLCO%a 46.0 6 3.5 14–94
CPI 51.9 6 2.6 36–76
All participants were Caucasian. CPI, composite physiologic index;
DLCO%, carbon monoxide diffusing capacity percentage predicted;
FEV1%, forced expiratory volume in 1 s percentage predicted; FVC%,
forced vital capacity percentage predicted. aData missing (n = 1).
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CA, USA). Murine lung mRNA was used to generate cDNA.
The Mouse Unfolded Protein Response RT2 Profiler PCR Ar-
ray (v.3.0; Qiagen) was used according to the manufacturer’s
instructions, and array data (Supplemental Data) were ana-
lyzed by using PCR Array Data Analysis software (Qiagen).
The semiquantitative real-time PCR data for each target gene
were expressed as 22DDCt relative quantitation vs. endoge-
nous control, with error bars representing the SEM.
Neutralization of IL-17A bioactivity
Neutralization of circulating IL-17A was performed as de-
scribed (3, 5), with an adenovirus encoding soluble murine
IL-17A receptor fusion protein (Ad-IL-17R:Fc), a generous gift
from Dr. Jay K. Kolls (Pittsburgh, PA, USA) (32). The control
vector, an adenovirus serotype 5 vector encoding the firefly
gene luciferase, was purchased fromWelgen (Worcester,MA,
USA). Recombinant adenovirus expressing a fusion protein
consisting of the murine IL-17RA extracellular domain with
the murine IgG CH2 and CH3 domains was generated by
subcloning the murine IL-17R cDNA (16) (EcoRI–*SalI) into
pACCMV (obtained from Robert Gerard, University of Texas
Southwestern Medical Center, Dallas, TX, USA), which con-
tains (sequentially) 1.3 map units of sequence taken from the
left end of the adenovirus 5 (Ad5) genome, the cytomegalo-
virus (CMV) early promoter; the pUC19 polylinker, simian
virus 40 splice, and poly(A) signaling sequences; and map
units 9 through 17 of the AdS genome. The recombinant
plasmid was cotransfected into the 293 cell packaging line,
together with the large adenoviral plasmid pJM17 (obtained
from Frank L. Graham McMaster University, Hamilton, ON,
Canada) by a calcium phosphate coprecipitation method. As
described by Graham and Prevec (16), 293 cells constitutively
express the adenoviral E1A and E1B proteins and support the
replication of ElA-defective mutants. pJM17 supplies the re-
mainder of the AdS genome, but its size exceeds the packag-
ing limit for adenovirus. Adenoviral genomes formed by
recombination between the pJM17 vector and the pACCMV
vector containing the inhibitor expression construct were
replication defective and were effectively packaged to form
infectious virions. C57-BL6 mice were subjected to tail vein
injections of Ad-lL-17R:Fc or an adenovirus encoding firefly
luciferase (Ad-LUC) at 109 plaque forming units (PFU) per
animal. Three days later, these mice were subjected to BLEO
injury. Three weeks later, the mice were euthanized.
Immunohistochemistry
Staining for DAF and IL-17A was performed on 4 mm tissue
sections, according to a published description, with slight
modifications (13). For IL-17A, antigen epitopeswere exposed
by using Triton X-100 in PBS (0.1%; 10 min) followed by in-
cubation with the primary antibody (1:500; R&D Systems,
Minneapolis, MN, USA). Sections were then subjected to the
protocol described in the manufacturers’ instructions in the
ABC Staining Kit (Vector Laboratories, Burlingame, CA,
USA) and the Fast Red Substrate kit (HK182-5K; Biogenex,
San Ramon, CA, USA). In brief, sections obtained from
paraffin-embedded, formalin-fixed lungs underwent antigen
retrieval treatment, followed by 5 min peroxide and protein
blocks (13 Power Block; Biogenex). The sections were then
incubated with the following primary Abs: rabbit anti-mouse
C9 receptor-1 related isoform Y (Crry; 1:200) and rabbit anti-
mouse DAF (1:200; Santa Cruz Biotechnology) and the corre-
sponding rabbit IgG (Jackson ImmunoResearch Laboratories).
The sections were washed and incubated with MACH 2 Rabbit
HRP-Polymer (Biocare, Concord, CA, USA) for 30min and then
stained with ImmPACT DAB (Vector Laboratories) for 2 min.
Nuclei were counterstained with hematoxylin.
In vivo delivery of RNA interference
Single-duplex siRNA sequences that targeted il17a or non-
targetingcontrol (f) siRNA(DharmaconTechnologies,Pittsburgh,
PA, USA) were used.
The siRNA sequences used in the in vivo experiments are:
nontargeting (f) siRNA: sense, 39-CGGUAACAACGCGUA-
CACGUU-59, antisense, 59-CGUGUACGCGUUGUUACCGUU-39;
il17a siRNA: sense, 39-CUUUCAGGGUCGAGAAGAUUU-59,
antisense, 59-AUCUUCUCGACCCUGAAAGUU-39. In brief,
50 mg of siRNA suspended in 50 ml volume was instilled
oropharyngeally in the mice.
Hemolytic activity
To determine the percentage of C9-mediated hemolysis, we used
a published protocol with minor modifications (33). In brief, we
measured triethanolamine-C9 hemolysis (TA-CH). We used
sheep erythrocytes (CS1112S; Colorado Serum, Denver, CO,
USA) as a positive control to determine 100% lysis in ammonia
lysis buffer. The absorbance of the assay at 100% lysis was set at
0.5. Two sets of coated red blood cells (RBCs) added to diluted
normal or IPF plasma (1:50) and TA-CH buffer were prepared.
Onesetof these sampleswas incubatedat roomtemperature, and
the second setwas incubated at 30°C for 30min. The 96-well flat-
bottomed plate was tapped every 10 min during the period of
incubation. At the end of this period, TA-CH buffer was added.
Reactants were centrifuged, and the supernatants were read at
540 nm.
Statistical analyses
Results are expressed as means 6 SEM. A Student’s t test and
1-way ANOVA with Bonferroni post hoc test were performed
with Prism v.3.0 forWindows (GraphPad, San Diego, CA, USA)
(26). Significance level was set at P, 0.05.
RESULTS
IL-17A activates C9 by modulating the mRNA
and protein expression of the C9 components
in vitro
Microarray gene analyses (Affymetrix; Thermo Fisher
Scientific) of normal primary human SAECs exposed to
IL-17A for 24 h revealed a;5- and;1.75-fold induction of
C3 and C9 factor B mRNA, respectively (Table 2; N = 5
donor lungs), and ;1.4-fold induction of GRK5. This
positive feedback regulation by IL-17A is corroborated by
findings inmurine tracheal epithelium (2), skin fibroblasts
(10), human proximal tubular epithelium (8), and human
colonic subepithelialmyofibroblasts (9).We also observed
;4.3- and 2-fold induction of IL8 and -6, respectively; and
a ;1.6-fold induction of IL1B. Further, upregulation of
chemokine (C-X-C motif) ligand (CXCL) -1, -2, -3, -5, -6,
and -16wasobserved.WeusedRNAisolated fromnormal
primary human AECs exposed to IL-17A for 24 h and
detected the transcript induction of theC9 componentsC3,
C5, C9 factor B, C3aR1, and C5aR1 (Fig. 1A). Immunoblot
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analyses of AEC lysates revealed a loss of the C9 inhibitor
DAF and an induction of C3aR and C5aR (Fig. 1B). Fur-
ther,wecorroboratedour findingsonC3mRNAinduction
bymeasuring active C3a by ELISA (Fig. 1C).We observed
a dose-dependent increase in C3a synthesis by the AECs
thatwas significantat thehigherdosesof10and100ng/ml.
Finally, we confirmed our observations on IL-17A-
mediated loss of DAF (Fig. 1D) by performing immuno-
cytochemistry analyses to assess DAF localization. Our
findings indicated the loss of membrane-bound DAF
in human AECs exposed to IL-17A. Collectively, our
findings indicated that IL-17A regulates the components
of the C9 cascade, at both the transcription and the trans-
lational levels.
IL-17A deficiency protects against
BLEO-induced lung fibrosis, collagen
deposition, and lung injury
To define the role of IL-17A in a BLEO model of lung
fibrosis and epithelial injury, we used il17a2/2 mice. We
determined the temporal expression pattern of local il17a
TABLE 2. IL-17A upregulates C9-related genes in normal human primary small airway epithelial cells
Functional category Affymetrix ID Gene Gene name
IL-17A
P FDR Fold vs. control
C9-related protein 17006949 CFB C9 factor B 7.55E–03 3.62E–01 1.74
16867784 C3 C9 component 3 3.52E–05 1.31E–01 5.17
16709822 GRK5 GPCR kinase 5 2.12E–03 2.92E–01 1.40
16967794 CXCl1 CXCL 1 8.81E2-03 3.70E2-01 1.85
16976844 CXCL2 CXCL 2 3.92E2-04 2.05E2-01 1.94
Chemokine ligands 16976833 CXCL3 CXCL 3 6.27E2-04 2.29E2-01 2.75
16976827 CXCL5 CXCL 5 7.25E2-05 1.52E2-01 10.97
16967779 CXCL6 CXCL 6 7.59E2-03 3.62E2-01 3.22
16840113 CXCL16 CXCL 16 2.20E2-02 4.63E2-01 1.59
Interleukins 16901986 IL1B IL-1b 1.52E2-03 2.67E2-01 1.63
17044177 IL6 IL-6 (IFN-b2) 5.42E2-04 2.28E2-01 2.08
16967771 IL8 IL-8 1.89E2-04 1.75E2-01 4.34
FDR, false discovery rate.
Figure 1. IL-17A activates C9 by modulating the mRNA and protein expression of the C9 components in vitro. A) Normal human
primary AECs were exposed to recombinant human IL-17A (100 ng/ml; 24 h). Subsequent to RNA isolation, cDNA was
generated and subjected to real-time quantitative PCR analyses. Means 6 SEM; Student’s t test. B) Protein lysates from AECs
exposed to recombinant human IL-17A (100 ng/ml; 4 h) were subjected to immunoblot analysis against C3aR, C5aR, DAF, and
vinculin. C) Conditioned medium collected from AECs exposed to the indicated doses of IL-17A for 4 h was analyzed for active
C3a by ELISA. Means 6 SEM. D) AECs exposed to IL-17A (100 ng/ml; 4 h) were methanol ﬁxed, immunostained for DAF, and
counterstained with DAPI. Results represent 3 independent experiments. Scale bars, 100 mm.
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mRNA in BLEO-injured wild-type mice. Whole-lung
mRNA analyses demonstrated that il17a levels in the
injured lungs were increased by over ;2-fold by d 7
(Fig. 2A). As shown in the schema in Fig. 2B, wild-type
and il17a2/2 mice were subjected to BLEO injury and
euthanized at d 21. We then determined collagen de-
position quantitatively by using the standard hydroxy-
proline assay on the left lung (Fig. 2C) and observed
significantly lower levels of collagen compared to that
in the diseased wild-type group. Histopathological as-
sessments show lung architecture (hematoxylin and
eosin; Fig. 2D) and connective tissue distribution
(Masson’s blue trichrome). BLEO-injured wild-type
mice were severely scarred, whereas il17a2/2 mice in-
jured with BLEO had near normal lung architecture.
Our results confirm those in a previous report (4) that
il17a2/2 mice subjected to BLEO injury are protected
from lung fibrosis and collagen deposition.
We next investigated the effects of BLEO on epithelial
injury in il17a2/2 mice. Reports showed that circulating
KL6/MUC-1 levels reflect greater alveolar permeability in
sleepapnea (34), during acute exacerbations of IPF (19, 20),
in patients with rapid IPF progression (21), and is a good
candidate prognosticmarker in IPF (22, 23).Wemeasured
KL6/MUC-1 in the plasmaofwild-type and il17a2/2mice
withBLEO injuryanddetected lowerplasmaKL6/MUC-1
in the il17a2/2mice (Fig. 3A) suggesting a suppression of
BLEO-mediated AEC injury. Further, data in Fig. 3B
showed lower levels of caspase-3/7 in il17a2/2mice with
BLEO injury compared with those in wild-type mice.
Taken together, these data suggest that il17a2/2 mice
in this model are protected from BLEO-induced lung
fibrosis and AEC injury.
Since epithelial injury in IPF is strongly related to
ER stress (14–17), we addressed ER stress in our
model. Prior reports indicate that IL-17A-dependent
lung injury is related to ER stress during viral in-
fection (18) and LPS exposure (1). Buildup of large
amounts of misfolded protein in the ER leads to acti-
vation of the unfolded protein response (UPR) path-
ways, which initially protect the cells, but eventually
lead to apoptosis. The UPR involves the activation of 3
transmembrane sensors—PKR-like ER kinase (PERK),
ATF6, and inositol-requiring enzyme (IRE)-1—all of
which are initially bound by ER chaperone Ig heavy-
chain–binding protein (BiP). UPR triggers BiP to release
these sensors wherein, PERK decreases protein trans-
lation via induction of phospho-eIF2a (eukaryotic
Figure 2. IL-17A deﬁciency protects against BLEO-induced lung ﬁbrosis and collagen deposition. A) C57-BL6 wild-type mice were
subjected to an intratracheal instillation of PBS or BLEO (0.025 U) on d 0 and euthanized at the indicated time points. RNA
isolated from lung homogenates was subjected to real-time quantitative PCR. Means 6 SEM; Student’s t test. B) Time line of
exposure of mice to PBS or BLEO until euthanasia. C) Left lungs were analyzed for hydroxyproline (n = 11–12/group). Means6 SEM;
1-way ANOVA and Bonferroni. D) Histopathologic examination showed that BLEO-induced ﬁbrosis and collagen deposition were
lower in the il17a2/2 mice. Results are representative of 3 independent experiments. Scale bars, 100 mm.
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translation initiation factor), ATF6 induces the synthesis
of folding chaperone proteins like BiP, and IRE-1 induces
the synthesis of protein degradation enzymes. Notably,
mRNA analyses of the lungs of BLEO-injured il17a2/2
mice revealed lower levels of ER stress as indicated by
lower atf4 expression (Fig. 3C), which is activated by the
PERK pathway; a lower atf6 trend in conjunction with
higher levels of atf6 inhibitor atf6b (Fig. 3D, E); and more
protein translation and less protein folding, as indicated
by lower levels of eukaryotic translation initiation factor
2A (eif2a; Fig. 3F) and of protein disulfide isomerase
family A (pdia3) (Fig. 3H), respectively. Again, eif2a and
pdia3 are triggered by the PERK pathway (35). We ob-
served downregulation of stress-associated ER protein
1 (serp1; Fig. 3G; or ribosome-associated membrane
protein 4) which is a co-chaperone and an interacting
partner for the epithelialNa+ channelb-subunit (bENaC).
We observed downregulation of p97/valosin-containing
protein-interacting membrane protein (vimp1) (Fig. 3I),
which is associated with the ER-associated protein degra-
dation (ERAD) or the IRE-1 pathway.We also observed the
recoveryofosteosarcomaamplified9 (os9) (Fig. 3J; amplified
Figure 3. IL-17A deﬁciency protects against BLEO-induced cellular apoptosis and ER stress in the lung. A) Plasma from lungs
described in Fig. 2B was analyzed for the AEC marker KL6/MUC-1 by ELISA (n = 11–12/group). Means 6 SEM; 1-way ANOVA
and Bonferroni. B) Supernatants of lung homogenates from the right lungs were subjected to caspase-3/7 luciferase assay
(n = 11–12/group). Means 6 SEM; 1-way ANOVA and Bonferroni. C–K) RNA was isolated from right lung homogenates, and cDNA
was subjected to real-time PCR reactions. The speciﬁc genes were atf4 (C), atf6 (D), atf6b (E), eif2a (F), serp1 (G), pdia3 (H),
vimp1 (I), os9 (J ) and scap (K) (n = 5–6/group). Means 6 SEM; 1-way ANOVA and Bonferroni (F–I, K), Newman-Keuls (C, E, J ).
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in osteo-sarcomas), which is also a component of the ERAD
pathway.Thisgene is a specificbindingpartnerof theNa-K-
2Cl cotransporter (36). Finally, although we observed the
upregulation of sterol regulatory element-binding protein, a
cleavage-activating protein (Fig. 3K) in response to BLEO
injury, we detected no changes in il17a2/2mice with BLEO
injury. The above findings present several ER stress–related
genes regulated by expression of IL-17A. Collectively, our
observationsprovidedcompelling evidenceof the role of IL-
17A in lung injury in our model.
IL-17A deficiency protects against
BLEO-induced local C9 activation
Wenext investigated the local effects of il17a deficiency on
the C9 components active C3a and active C5a and the
terminalC9 complex solubleC5b-9. Increased levels ofC3a
and C5a in BALF were reported in transfusion-related
acute lung injury (37) and in chronic rejection after lung
transplantation (38). We have reported that BLEO injury
induces local C3a andC5a levels at d 14 that persist at d 28
(26).Wehavealso reported that blocking receptors forC3a
andC5a inmicewith fibrotic lungs, effectively suppressed
local C3a, C5a, and C5b-9 levels (26). Elevated tissue de-
position of C5b-9 was reported during the acute rejection
phase after lung transplantation (37). In this study, we
observed that BLEO-injured mice with il17a deficiency
have lower levels of local C3a (Fig. 4A) and C5a (Fig. 4B),
and soluble C5b-9 (Fig. 4C), compared to wild-type mice
withBLEO injury.Collectively, these results support a role
for IL-17A in driving C9 activation in the pathogenesis of
lung fibrosis.
Neutralization of IL-17A prevents BLEO-
induced lung fibrosis, cellular apoptosis,
and the loss of C9 inhibitory proteins
To further confirm the role of IL-17A in thedevelopmentof
lung fibrosis and C9 activation, we used Ad-IL-17R:Fc, a
vector encoding a soluble murine fusion protein that
neutralizes circulating IL-17A and IL-17F by preventing
the binding to their receptors and activation of down-
stream signaling. We have reported that neutralizing
IL-17A with the use of Ad-IL-17R:Fc blocks chronic
lung allograft rejection (5) and local TGF-b expression
(3). Thus, in this study we hypothesized that blocking
IL-17A/F from binding to their receptors would pre-
vent BLEO-induced lung fibrosis and C9 activation.
C57-BL/6micewere administered i.v. injections of Ad-
IL-17R:Fc or Ad-LUC 3 d before BLEO injury (Fig. 5A).
It should be noted that Kolls et. al (39) have demon-
strated that only IL-17A can be blocked by a soluble
receptor protein, whereas IL-17F requires amembrane-
bound IL-17 receptor. We observed that mice which
received adenoviral vectors expressing IL-17R:Fc
had lower levels of lung fibrosis (Fig. 5B) and IL-17A
expression (Fig. 5C). Furthermore, immunofluores-
cence analysis revealed high levels of the myofibro-
blast differentiation marker, a-smooth muscle actin
(a-SMA; staining in green) expression in the fi-
brotic foci (Fig. 5D; top) of lungs in the control vec-
tor Ad-LUC group, and this effect is suppressed
in the Ad-IL-17R:Fc group. Moreover, the epithelial
marker, zonula occludens-1 (ZO-1-staining in red), is
well defined in the lung architecture of normal mice.
Furthermore, the BLEO-injured group that received
Ad-IL-17R:Fc was protected from cellular injury, as
indicated by TUNEL staining analyses (Fig. 5D; bot-
tom). We have reported that IL-17A mediates the loss
of DAF and Crry (rodent analog of the human CD46)
in normal immortalized rat AECs in vitro (38). We
have also reported the loss of DAF and Crry in murine
models of obliterative bronchiolitis (38). Further, we
reported the loss of DAF and CD46 in the lung epi-
thelium of patients with IPF compared with normal
lungs (13). Our previous data demonstrated that C9 ac-
tivation is significantly higher in mice with lung fibrosis
(26). In this report, panels in Fig. 5E show that normal
lungs have abundant expression of the earlyC9 inhibitors
or inhibitors of theC3 andC5 convertasesDAF andCrry,
on both the airway and the alveolar epithelial cells.
BLEO injury in the Ad-LUC group resulted in loss of
these epithelial proteins. Ad-IL-17R:Fc group protected
against loss of the C9 inhibitors Crry and DAF. Taken
together, our studies further confirm the role of IL-17A
in regulating the C9 cascade in the pathogenesis of lung
fibrosis.
Figure 4. IL-17A deﬁciency protects against BLEO-
induced local C9 activation. The BALF samples
collected for the analysis shown in Fig. 2 were also
analyzed for C3a (A), C5a (B), and C5b-9 (C)
levels by ELISA (n = 7–8/group). Means 6 SEM.
One-way ANOVA, Newman-Keuls (A, C), and
Bonferroni (B).
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Figure 5. Neutralization of IL-17A prevents BLEO-induced lung ﬁbrosis, apoptosis, and loss of C9 inhibitors. A) C57-BL6 mice
received tail vein injections of the adenoviral vectors 3 d before BLEO injury and then were euthanized 21 d after injury. B)
Histopathologic examination with hematoxylin and eosin indicates scarred lung in the Ad-LUC groups, which is prevented with
administration of the Ad-IL-17R:Fc. C) Tissues were immunostained with antibodies against IL-17A, using secondary alkaline red
phosphatase and counterstained with hematoxylin and eosin. D) Top: colocalization of ZO-1 and a-SMA using ﬂuorescent
labeling in the lungs of Ad-LUC and Ad-IL-17R:Fc groups. Nuclei were counterstained with DAPI. Bottom: TUNEL staining with the
analyses of number of cells staining TUNEL+ (n = 5/group). Means 6 SEM; 1-way ANOVA and Bonferroni. E) Immunostaining of the
C9 inhibitors DAF and Crry expression in the epithelial cells of lungs of Ad-LUC and Ad-IL-17R:Fc groups. Normal expression of these
proteins are diminished or lost in the Ad-LUC group with BLEO injury, and this is presented in the Ad-IL-17R:Fc despite BLEO injury.
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RNA interference–mediated gene silencing of
il17amitigates progression of fibrosis and the
lung deposition of collagen and C9
We next examined the effects of the targeted suppression
of il17a expression using the RNA interference (RNAi)
approach in a clinically relevantmodel of lung fibrosis.We
have reported this model and the extent of fibrosis (26, 30,
31). BLEO-injured mice with significantly scarred lung
tissue were subjected to oropharyngeal instillation of
siRNAspecific to il17aor nontargeting control siRNA (Fig.
6A). Figure 6B demonstrates the gene silencing efficacy of
the siRNA in BLEO-injured tissues. Figure 6C supports
our hypotheses that lack of expression of IL-17Amediates
a profound antifibrotic effect, with significant suppres-
sion of collagen deposition as confirmed by measuring
Figure 6. RNAi-mediated gene silencing of
il17a mitigates progression of ﬁbrosis and lung
deposition of collagen and C9. A) PBS or BLEO
(0.025 U) was instilled intratracheally in C57-
BL6 mice on d 0, followed by oropharyngeal
instillation of 50 mg RNAi on d 14. Tissues were
harvested on d 28. B) Formalin-ﬁxed parafﬁn-
embedded tissues were immunostained with
antibodies against IL-17A using secondary alkaline
red phosphatase and counterstained with hema-
toxylin. C) Left lungs were analyzed for hydrox-
yproline (n = 11–12/group). Means 6 SEM; 1-way
ANOVA and Bonferroni. D) Histopathological
examination showed that BLEO-injured ﬁbrotic
lung and collagen deposition were reduced by
silencing il17a. Scale bars, 100 mm. E, F) We
analyzed caspase-3/7 (E) and C5b-9 expressions
(F) in the supernatants of the lung homoge-
nates by the luciferase assay and ELISA,
respectively (n = 10–12/group). Means 6
SEM; 1-way ANOVA and Bonferroni. Results
are representative of 3 independent
experiments.
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hydroxyproline synthesis in the left lung. Figure 6D shows
the lung architecture of BLEO-injured mice and the cor-
responding extensive collagen deposition. The mice that
therapeutically received il17a-specific siRNA showed sig-
nificant recovery and corresponding lower levels of col-
lagen deposition.Wenext assessed the level of lung injury
in thesemice bymeasuring the caspase-3/7 levels (Fig. 6E)
and observed that il17a siRNA-treated mice had lower
levels of cellular apoptosis. We then observed the sup-
pression of lung C5b-9 deposition in BLEO-injured mice,
as measured in lung homogenates (Fig. 6F). Collectively,
these results suggest that the therapeutic blockade of il17a
arrests fibrotic progression with suppression of local col-
lagen and C9 deposition.
Hemolytic activity in IPF
The involvement of the C9 system in lung host defense
mechanisms has been demonstrated in several lung dis-
eases including IPF. Our earlier reports demonstrated el-
evated levels of active C3a and C5a (13) and the soluble
terminal C9 complex C5b-9 (26) in the plasma and BALF
derived from patients with IPF and normal nonsmoking
healthy subjects. In this report, we investigated the func-
tional state of the C9 components using standard hemo-
lytic assays in the plasma samples derived from patients
with IPF and normal subjects. We detected significant
functional activity in plasma of patients with IPF by using
antibody-coated sheep RBCs. Plasma samples from pa-
tients with IPF induced 746 8% lysis of target RBCs. We
detected significantly lower levels of hemolytic activity in
the plasma samples of healthy normal volunteers at 326
9%lysis of targetRBCs,whichwasnot different fromheat-
inactivated plasma samples from patients with IPF (33 6
5%) or those of healthy normal volunteers (236 6%) (Fig.
7). These results provide a clinical association and rele-
vance to our findings that suppression of C9 activation is
essential to mitigate further fibrotic responses (Supple-
mental Data).
DISCUSSION
The present study is the first to demonstrate the role of
IL-17A in driving C9 activation in a murine model of lung
fibrosis. In addition to using mice that were genetically
deficient in il17a, we employed adenoviral vectors that
express soluble murine IL-17 receptor fusion protein to
demonstrate that lack of IL-17A signaling suppresses local
C9 activation. In addition,we show that therapeuticRNAi-
mediatedgene silencingof il17amitigates lung fibrosis and
local C9 and collagen deposition and adds support to the
interpretation that limiting C9 by neutralizing IL-17Amay
be one of the potential mechanisms in ameliorating lung
fibrosis. Inaddition to theeffectsof IL-17AdeficiencyonC9
activation,we have also confirmed that these tissues are
indeed protected from cellular injury, as indicated by
KL-6/MUC1, caspase-3/7, ER stress-related genes, and
TUNEL analyses. Our clinical findings demonstrate
evidence of C9 in patients with IPF, as indicated by the
presence of hemolytic activity.
IL-17A, a major orchestrator of sustained neutrophilic
mobilization (40), has been linked to IPF (4, 41). The long-
prevailing hypothesis sustains the idea that AECs are
victims of the surrounding inflammatory microenviron-
ment (11). Wilson et al. (4) have shown that BLEO-injured
lungs have high levels of IL-17A. Early reports by Strunk
et al. (42) showed thathumanAECs synthesizeC9proteins,
including C2, C3, C4, C5, and factor B, as detected by
immunoblot techniques in AECs and whole lungs. Our
microarray studies in SAECs showed that IL-17A induced
mRNAexpressionof IL6, -8, and -1B in lungepithelial cells.
It is possible that these cytokines enhance the local syn-
thesis of C9 proteins and add to the milieu. Van Kooten
et al. (8) demonstrated the role of IL-17A in regulating local
inflammatory responses by showing that after a 72 h ex-
posure to IL-17A, human proximal tubular epithelial cells
synthesized C3 protein but not C2, C4, or factor H. Our
current findings show that IL-17A induces the mRNA
synthesis of C3, C5, and factor B as early as in 24h inAECs
(the relevant cell type in lung fibrosis) and the synthesis
of active C3a as well as the protein expression of re-
ceptors for C3a and C5a within 4 h. Sugihara et al. (9)
reported that blockade of ERK and p38MAPK pre-
vented IL-17A-induced C3 mRNA expression by hu-
man colonic subepithelial myofibroblasts as early as
12 h. We have observed that IL-17A mediates epithe-
lial injury via TGF-b-p38MAPK signaling (3) and that
TGF-b, C3a, and C5a each mediate epithelial injury via
p38MAPK activation (13). Our studies and reports by
others demonstrate that local synthesis of C9 proteins is
a steady source of inflammatory responses in the lung,
specifically for the AECs.
The importance of IL-17A in IPF was underscored
when Wilson et al. (4) identified elevated expression of
IL-17A in BALF from a lung with regions of marked in-
flammatory foci within the parenchyma, surrounded by
dense collagen deposits. They also reported that IL-17A-
driven fibrosis is suppressed by IL-10, that IL-17A and
TGF-bmay have cooperative roles in the development of
fibrosis, and that IL-1b-induced fibrosis, which mimics
BLEO-induced fibrosis, is dependent on IL-17A (4). Other
Figure 7. Hemolytic activity in IPF. Hemolytic activity was
assessed in 7 normal patients and 23 with IPF, with or without
heat inactivation. Means 6 SEM; 1-way ANOVA and post hoc
Bonferroni.
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studies also show an increasing role for T cells in murine
models of IPF (43–45) and IL-17A derived from T cells
associated with antigen-induced murine pulmonary fi-
brosis (46). Bone marrow transplantation from il17a2/2
donors or treatment with anti-IL-17A neutralization anti-
bodies at late stages attenuated pneumonitis and fibrosis
in virus–infected mice who have received bone marrow
transplantation, suggesting that hematopoietic-derived
IL-17A is essential for development of pathology (6). Our
in vivo studies of il17a2/2 mice and a low-dose (0.025 U)
model of BLEO studied over a period of 3 wk show that,
indeed, chronic injury is prevented by il17a deficiency.
This model allows us to study the mechanisms of lung
fibrosis in the context of C9 activation in a remodeled lung
and the effects of therapeutic administration of il17a
siRNA.Further,we showed that il17amRNAexpression is
significantly high compared to that in a normal lung and
drops to baseline at d 14. It is likely that the protein ex-
pression would be sustained until d 14. Our model con-
trasts with the report byWilson et al. (4), in that they used
triple instillations of a high dose (0.15 U) of BLEO and
terminated their studies in 1 wk. They also reported sig-
nificantweight loss in theBLEO-injuredmice, despite il17a
deficiencyat1wk.Wefound significant local andsystemic
lung injury at d 21, as indicated by caspase-3/7 and the
AEC injury marker KL6/MUC-1.
IL-17A has been reported to induce ER stress and ex-
acerbate LPS-induced lung injury (1) and respiratory
syncytial virus-induced lung pathology (18). Elevated lo-
cal levels of BLEO-induced IL-17A and IL-6 levels were
exacerbated by increased extracellular adenosine levels
andprogressive lung fibrosis (47).Korfei et al. (15) reported
that severe ER stress response in theAECs of patientswith
sporadic IPF may underlie the apoptosis of this cell type
and development of fibrosis in IPF, by observing high
levels of ATF4 and -6 in AECs. Yuan et al. (48) have re-
ported that inhibition of the ER stress pathway protects
against cigarette smoke extract–induced humanbronchial
epithelial cell apoptosis by regulating the activity of eIF2a.
Pacello et al. (49) reported that PDIA3 promotes the
proinflammatory response elicited by cells in response to
infections. SERP1 is a novel cochaperone and regulator of
epithelial Na(+) channel expression (50). SERP1 controls
the early biogenesis of membrane proteins (50). Hofmann
et al. (52) reported that fine mapping and mRNA expres-
sion studiespointed toOS9as themost likely candidate for
the underlying risk factor for sarcoidosis. The OS9 protein
plays an important role in ERAD and acts during TLR-
inducedactivationofmyeloid cells (51).Wehaveobserved
upregulation of atf4, serp1, pdia3, vimp1, and os9, with
downregulation of atf6b and eif2a, as expected. Both vimp1
and os9 belong to the ERADpathway, but vimp1 is indeed
downregulated in il17a2/2 mice with BLEO injury, the
trend is reversed in the case of os9. It should be noted that
because the murine model in our studies addressed fi-
brosis rather than the inflammatory phase. Our studies
present compelling evidence for IL-17A-mediated localER
stress in chronic lung fibrosis, as indicated by the regula-
tion of the related genes.
It has been reported that IL-17RA (the receptor for
IL-17A) expression was necessary in both hematopoietic
and parenchymal cells to enable significant glomerular
C3 deposition in experimental glomerulonephritis (52).
House dust mite–mediated local C3a synthesis was
mitigated using IL-17A monoclonal antibodies in ex-
perimental allergic asthma (2). As we have previously
identified that blockade of receptors to C3a and C5a
mitigates progression of lung fibrosis (26), we explored
the possibility that C9 activation may underlie IL-17A-
mediated lung fibrosis. In the current report, we dem-
onstrate a previously unexplored role and a direct link
for IL-17A in the regulation of C9 activation and pro-
gression of lung fibrosis. Notably, in our studies, the
direct association between IL-17A andC9 activation held
up across a wide spectrum of IL-17A interventions. We
used 3 approaches to demonstrate the role of IL-17A in
regulating C9 in the pathogenesis of lung fibrosis. We
used il17a2/2mice to demonstrate the role of IL-17A in
driving local C9 activation. We also used the prophy-
lactic approach via adenoviral vectors overexpressing
soluble murine IL-17A receptor fusion protein to bion-
eutralize IL-17A before BLEO injury and showed pro-
tection against lung fibrosis and loss of C9 inhibitors.
Lastly, and most importantly, we used the therapeutic
approach of il17a-specific siRNA-mediated gene silenc-
ing and demonstrated protection against lung fibrosis
and mitigated local deposition of both collagen and C9.
To our knowledge, this is the first report to demonstrate
the therapeutic efficacy of IL-17A inhibition in arresting
the progression of lung fibrosis. We have bolstered our
findings by presenting data on caspase-3/7 in the same
tissues that were tested for C9 deposition. Thus, our
studies support our claim that neutralizing IL-17A will
ameliorate fibrosis by limiting C9 activation.
Finally, our clinical results demonstrate the presence of
C9 as measured by hemolytic activity. Lambre´ et al. (54)
reported the presence of C9 in IPF BALF samples and
measured the hemolytic activity. C9 activation leads to the
release of numerous C9 components that are potent mod-
ulators of macrophage, monocyte, and lymphocyte func-
tions such as phagocytosis, release of lysosomal enzymes,
oxygen metabolite generation, and antibody synthesis
(53). Our results show the systemic levels of C9 activity in
IPF patients. Clearly, C9 activity is significantly higher in
patientswith IPF than innormalhealthyvolunteers.When
these plasma samples from IPF patients were heat inacti-
vated, then the activity dropped 50-fold to a level com-
pared to thatofnormalvolunteers.Althoughweattempted
to correlate the lung function indices with hemolytic ac-
tivity, we did not detect a significant correlation owing to
the wide range of activity and the low number of patients
with IPF analyzed (data not shown).
Our studies present evidence, for the first time to our
knowledge, which definitively links IL-17A to C9 activa-
tion and leads to the pathogenesis of fibrosis. The possible
missing links in our studies would be the lack of use of
more clinical samples toanalyze thehemolytic activity and
compare those levels with the lung function indices and
with the local activity. Another possible missing link
would be to substantiate our therapeutic findings by
providing add-back therapy findings. Further, the com-
bined synergistic effects of IL-17A and the anaphylatoxins
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C3a and C5a, on AECs are unknown. Our studies in the
current report provide compelling evidence, but our
aforementioned concerns will be addressed in future
studies.
CONCLUSIONS
Our studies provide a missing link between IL-17A-
driven inflammation and eventual fibrosis. Although
IL-17A drives ER stress and apoptosis in the lungs on one
hand, it simultaneously drives the C9 cascade and aug-
ments the epithelial injury and profibrotic signaling
pathways. Thus, limiting the C9 cascade by neutralizing
IL-17A may be one of the potential mechanisms in ame-
liorating lung fibrosis.
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